Understanding how brain tumors adapt to targeted therapies
Official title: Brain microenviornment-dependent lineage plasticity drives adaptation to targeted therapy in malignant gliomas
Funded at University of California Los Angeles · NIH-10997865 · Data updated 2026-11-12
This study is looking at how brain tumors called gliomas change and resist treatment, with the goal of finding better and more personalized ways to help patients with this type of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $41,328 |
| NIH project number | 1F30CA295084-01 |
| Project ID | NIH-10997865 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with malignant gliomas, particularly those who have not responded well to existing therapies.
✕Less likely to help
Patients with non-malignant brain tumors or those who are not diagnosed with gliomas may not benefit from this research.
What this research studies
This research investigates how malignant gliomas, a common and deadly type of brain cancer, adapt to targeted therapies. By examining the brain's unique environment, the study aims to uncover the mechanisms that allow these tumors to resist treatment. Using advanced techniques like single-cell RNA sequencing and genetic tracing, researchers will analyze how tumor cells change their characteristics in response to therapy. This could lead to more effective and personalized treatment strategies for patients with glioblastoma.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with malignant gliomas, potentially increasing survival rates.
How similar studies have gone: Previous research has shown promising results in understanding tumor plasticity and resistance mechanisms in other cancers, suggesting potential for success in this area as well.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Cadet, Dimitri — University of California Los Angeles
- Study coordinator: Cadet, Dimitri
Related research
Other NIH-funded projects on the same topics.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
-
Targeted therapy for splicing-factor mutant myeloid cancers
Aims to test a dual drug strategy targeting ATR and PARP pathways in adults with splicing-factor mutant acute myeloid leukemia or related myeloid diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.